Loading...
Loading...
HOOK| Name | Value |
|---|---|
| Revenues | 7.4M |
| Cost of Revenue | 1.3M |
| Gross Profit | 6.1M |
| Operating Expense | 24.3M |
| Operating I/L | -18.1M |
| Other Income/Expense | 6.2M |
| Interest Income | 1.2M |
| Pretax | -24.7M |
| Income Tax Expense | 0.2M |
| Net Income/Loss | -24.8M |
HOOKIPA Pharma Inc. is a clinical stage biopharmaceutical company specializing in developing immunotherapeutics for infectious diseases and cancers. The company's lead product candidates include HB-101 for cytomegalovirus-positive donors awaiting kidney transplantation, and HB-201 and HB-202 for human papillomavirus 16-positive cancers. Additionally, HOOKIPA Pharma Inc. has preclinical stage products targeting prostate cancer and mutated KRAS in pancreatic, colorectal, and lung cancer. The company generates revenue through the development and potential commercialization of its immunotherapeutic products, as well as through collaborations with companies like Gilead Sciences, Inc. for preclinical research programs on potential vaccine products for Hepatitis B Virus.
